Company intelligence / Profile preview

BioCell

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

BioCell Innovations is a Singapore-based biotechnology company specializing in the development of next-generation CAR-T and immune cell therapies. The company's core technology is a proprietary manufacturing process designed to significantly reduce cytokine release syndrome (CRS) and other toxicities without compromising therapeutic potency. Its pipeline includes humanized CD19 CAR-T cells and CD19/CD20 bispecific CAR-T cells for B-cell malignancies, as well as programs for solid tumors. BioCell Innovations aims to make advanced cell therapies safer, more effective, and more accessible through strategic partnerships and innovative process engineering.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyGene therapy
Industry: Biotech

Partnerships

Thermo Fisher ScientificScaleReady

Beyond the preview

Go deeper on BioCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCell.

Explore the full profile